Prognostic value of the ALBI grade among patients with single hepatocellular carcinoma without macrovascular invasion

Heng Zou (✉ zhcsuxy@csu.edu.cn)

The Second Xiangya Hospital, Central South University

Wenhao Chen

The Second Xiangya Hospital, Central South University

Huan Wang

Central South University of Second Xiangya Hospital

Li Xiong

The Second Xiangya Hospital, Central South University

Yu Wen

The Second Xiangya Hospital, Central South University

Jiangjiao Zhou

The Second Xiangya Hospital, Central South University

Research article

Keywords: Hepatocellular carcinoma, Overall survival, Tumor size, Albumin-bilirubin grade

Posted Date: June 2nd, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-30583/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at Medicine on June 18th, 2021. See the published version at <https://doi.org/10.1097/MD.00000000000026265>.

Abstract

Overview and objective: Although evidence for the application of albumin–bilirubin (ALBI) grading system to assess liver function in hepatocellular carcinoma (HCC) is available, less is known whether it can be applied to determine the prognosis of single HCC with different tumor sizes. This study aimed to address this gap.

Methods: Here, we enrolled patients who underwent hepatectomy due to single HCC from the year 2010 to 2014. Analyses were performed to test the potential of ALBI grading system to monitor the long-term survival of single HCC subjects with varying tumor sizes.

Results: Overall, 265 participants were recruited. The overall survival (OS) among patients whose tumors were ≤ 7 cm was remarkably higher compared to those whose tumors were > 7 cm. The Cox proportional hazards regression model identified the tumor differentiation grade, ALBI grade, and maximum tumor size as key determinants of the OS. The ALBI grade could stratify the patients who had a single tumor ≤ 7 cm into two distinct groups with different prognoses. The OS between ALBI grades 1 and 2 was comparable for patients who had a single tumor > 7 cm.

Conclusions: We show that ALBI grading system can predict disease outcomes of single HCC patients with tumor size ≤ 7 cm. However, the ALBI grade may not predict capability the prognosis of patients with single tumor > 7 cm.

Tables

Table 1 Baseline characteristics of 265 HCC patients

Variables	Total cohort (n = 265)	≤7 cm subgroup (n = 168)	>7 cm subgroup (n = 97)	P value (≤ 7cm vs > 7cm)
Age, years ^a	51 (43-60)	52 (41-60)	51 (44-60)	0.852
Male gender ^b	231 (87.2%)	147 (87.5%)	84 (86.6%)	0.832
Positive HBsAg ^b	228 (86.0%)	143 (85.1%)	85 (87.6%)	0.630
Total bilirubin, μmol/l ^a	13.4 (9.8-18.3)	13.3 (9.9-19.3)	13.5 (9.6-17.9)	0.749
Albumin, g/l ^a	38.4 (35.6-41.2)	39.1 (36.4-41.4)	37.9 (34.2-40.0)	0.010
ALBI grade ^b				0.036
1	147 (55.5%)	85 (50.6%)	62 (63.9%)	
2	118 (44.5%)	83 (49.4%)	35 (36.1%)	
Prothrombin time, s ^a	13.2 (12.2-14.4)	13.2 (12.1-14.3)	13.2 (12.3-14.4)	0.934
Platelet count, × 10 ⁹ /l ^a	151 (106-210)	135 (93-188)	195 (135-246)	< 0.001
Maximum tumor size, cm ^a	6.0 (3.5-9.0)	4.0 (3.0-5.5)	10.0 (8.0-14.0)	< 0.001
Serum AFP ≥ 400 ng/ml ^b	90 (34.0%)	46 (27.4%)	44 (45.4%)	0.003
Operative time, min ^a	180 (140-210)	170 (136-205)	180 (155-223)	0.015
Blood loss, ml ^a	300 (100-500)	200 (100-400)	400 (200-1000)	< 0.001
Major hepatectomy ^b	42 (15.8%)	6 (3.6%)	36 (37.1%)	< 0.001
Poor differentiation grade ^b	80 (30.2%)	42 (25.0%)	38 (39.2%)	0.015
Survival time ^a , mo	43 (25-61)	49 (37-62)	26 (15-57)	< 0.001

^aValues are median (interquartile range); ^bValues are number (%).

HCC, hepatocellular carcinoma; HBsAg, hepatitis B surface antigen; ALBI, albumin-bilirubin; AFP, α-fetoprotein.

Table 2 Prognostic factors for survival in the total cohort

Variables	Univariate analysis		Multivariate analysis	
	Hazard ratio	<i>P</i> value	Hazard ratio	<i>P</i> value
Age	0.79 (0.51-1.23)	0.298		
Gender	1.33 (0.75-2.36)	0.331		
Albumin-bilirubin grade	2.28 (1.57-3.32)	<0.001	2.10 (1.43-3.08)	<0.001
Prothrombin time	1.46 (1.03-2.07)	0.034	1.28 (0.90-1.83)	0.169
Platelet count	1.31 (0.88-1.95)	0.179		
Maximum tumor size	2.08 (1.46-2.96)	<0.001	1.72 (1.16-2.56)	0.007
Alpha-fetoprotein	1.42 (0.99-2.03)	0.054	1.16 (0.80-1.70)	0.435
Operation time	1.51 (1.06-2.15)	0.021	1.25 (0.86-1.83)	0.240
Blood loss	1.55 (1.05-2.28)	0.028	1.03 (0.67-1.58)	0.891
Major hepatectomy	1.55 (0.99-2.42)	0.054	0.95 (0.58-1.56)	0.837
Differentiation grade	1.67 (1.17-2.40)	0.005	1.47 (1.01-2.15)	0.045

Table 3 Multivariate analyses of prognostic factors for survival divided by tumor size

Variables	≤7 cm subgroup		>7 cm subgroup	
	Hazard ratio	<i>P</i> value	Hazard ratio	<i>P</i> value
Age	0.81 (0.43-1.54)	0.522	0.61 (0.29-1.29)	0.194
Gender	1.33 (0.59-3.01)	0.498	1.61 (0.65-3.96)	0.302
Albumin-bilirubin grade	2.37 (1.39-4.05)	0.002	1.74 (0.95-3.18)	0.072
Prothrombin time	1.47 (0.89-2.44)	0.133	0.93 (0.53-1.64)	0.798
Platelet count	1.80 (1.07-3.05)	0.027	1.12 (0.39-3.19)	0.840
Alpha-fetoprotein	1.45 (0.81-2.61)	0.213	0.97 (0.57-1.67)	0.924
Operation time	1.10 (0.65-1.89)	0.719	1.20 (0.68-2.12)	0.533
Blood loss	1.21 (0.63-2.32)	0.570	0.84 (0.47-1.49)	0.548
Differentiation grade	1.67 (0.97-2.86)	0.064	1.33 (0.77-2.31)	0.311

Introduction

Hepatocellular carcinoma (HCC) is a very aggressive form of cancer. Current statistics rank HCC as the sixth most prevalent cancer disease in the world. Also, cancer has been reported to be the 3rd most prevalent cause of cancer-associated deaths worldwide¹. Treatment of HCC has remained a challenge to date. When diagnosed early, resection can be performed to get rid of the affected part then other therapeutic options like chemotherapy and radiotherapy can be used to kill the tumors that could have metastasized. Therefore, surgical resection is still the main treatment option for single HCC². However, because this form of tumor is very aggressive, recurrence is common even after surgical resection; hence very early diagnosis is necessary to ensure successful treatment and to improve the disease outcome.

The guidelines of Barcelona Clinic for Liver Cancer staging system stipulates that hepatic surgery is only suitable for early-stage tumors (stages 0 and A: single tumors or multinodular tumors with size ≤ 3 cm, Child-Pugh A or B, PS 0, and ≤ 3 nodules with no vascular invasion)³. The size of a tumor is a significant determinant of disease outcomes of HCC patients. A tumor with large diameter correlates with worse clinical outcomes in HCC patients^{4, 5}. Johnson et al. put forward a novel way of assessing the function of the liver termed the albumin–bilirubin (ALBI) grade. This has been verified to be an ideal tool for evaluating the liver function of HCC patients. The model involves the use of only serum albumin and bilirubin and avoids subjective parameters like ascites and encephalopathy⁶. The ALBI grade was verified as a precise prognostic model for advanced HCC patients and receiving sorafenib⁷, for solitary HCC within the Milan criteria⁸, for early-stage HCC patients who have treated by radiofrequency ablation⁹, and for different BCLC stages of HCC¹⁰. However, the association between the size of single tumors of HCC patients and the ALBI grade is not sufficiently understood.

Herein, we examined the potential of ALBI grade to assess the clinical outcomes of HCC with varying tumor sizes.

Methods

Patients

Hepatocellular carcinoma (HCC) patients who received hepatectomy in our ward from 2010 through 2014 were recruited. The HCC was diagnosed by pathological examination of prepared liver specimens by a qualified pathologist. Only patients who had the following features were included in the study: ALBI grade 1 or 2 for liver function; no treatment for HCC before hepatectomy, single tumor without macrovascular invasion, and absence of lymph node metastasis. The patients were classified into subgroups on the basis of the size of tumors: group I, tumor sizes ≤ 3 cm; group II, tumor sizes > 3 and ≤ 5 cm; group III, sizes > 5 and ≤ 7 cm; group IV, tumor size > 7 and ≤ 10 cm; group V, tumor size > 10 cm. This study was

approved by the Institutional Ethical Board of Central South University. It also conformed to the guidelines of the Helsinki Declaration. Informed consent was waived for this retrospective study.

Definitions

We calculated the ALBI scores as follows: $\text{ALBI score} = 0.66 \times \log_{10}(\text{total bilirubin, } \mu\text{mol/l}) - 0.085 \times (\text{albumin, g/l})$. The following grading system was employed: grade I (≤ -2.60); grade II (-2.60 to ≤ -1.39); grade III (< -1.39)⁶.

Surgical methods

Indocyanine green test was carried out to assess liver function in hepatitis B virus (HBV) or hepatitis C virus infected individuals before the surgery. Preoperative remnant liver volume was mainly assessed by three-dimensional reconstruction and virtual hepatic resection among patients who underwent a major hepatectomy as per the methods described previously¹¹. Most of the patients received open hepatectomy through the right subcostal margin incision. However, a few selective patients (those with tumor size < 5 cm positioned in segments 2–6 of the liver) underwent laparoscopic surgery. Intraoperative ultrasonography was conducted to confirm the relationship between tumors and vessels and locate the satellite nodules when necessary. After determining resectability, anatomical liver resection was the preferred option in the case of sufficient future remnant liver functional reserve. Hepatectomy extent was considered minor resection or major (involving three/more Couinaud liver segments) and minor¹².

Post-surgery follow-ups

Follow-up periods were one month after discharge and every three months for the next two years as described in our previous study¹³. During the follow-ups, routine tests on blood, α -fetoprotein (AFP), imaging examinations, such as ultrasonography, contrast-enhanced CT/MRI, and liver function tests were performed. In the case of recurrence, the patients were taken through repeated hepatic resection, transcatheter arterial chemoembolization, ablation, or systemic therapies. These therapies were administered based on the hepatic function, tumor status, and the economic status of the patient. The OS was measured beginning from the first diagnosis of HCC (admission date) until last follow-up/death/January 2018.

Data analysis

Data involving continuous variables were assessed by the Mann-Whitney and *U* test and shown as Interquartile range whereas discrete variables were analyzed by Chi-square. Kaplan-Meier (KM) plot was employed in the determination of overall survival. The log-rank test was employed to make comparisons of survival rates. The multivariate Cox proportional hazard regression model was applied to identify independent prognostic factors for overall survival. These analyses were conducted using SPSS v25.0. A $p < 0.05$ represented statistically significant differences.

Results

Clinicopathological features

Precisely 265 HCC patients, including 231 males and 34 females (median age=51 yrs) [range: 21–77 yrs] were enrolled. A total of 60, 62, 46, 52, and 45 patients were classified in groups I, II, III, IV, and V, respectively. Those whose tumors were ≤ 7 cm presented a higher albumin level, a longer survival time, and a higher proportion of ALBI grade 2 HCC than those who had tumors that were > 7 cm ($P=0.010$, $P<0.001$ & $P=0.036$, respectively). However, patients who had tumor size ≤ 7 cm had a significantly low platelet count, a small tumor size, a short operative time, low blood loss, low rates of ALBI grade 1 HCC, AFP (alpha-fetoprotein) ≥ 400 ng/mL, major liver resection, and poor differentiation ($P<0.001$, $P<0.001$, $P=0.015$, $P<0.001$, $P=0.036$, $P=0.013$, $P<0.001$, & $P=0.015$, respectively). The baseline features of participants are presented in Table 1.

Survival

Among the 265 patients, the OS at 1 and 3 years reached 92.8% and 66.8%, respectively. No considerable differences in the OS were observed between the groups I and II ($P=0.525$), groups II and III ($P=0.439$), and groups I and III ($P=0.627$) (Figure 1A). A similar OS was noted between groups IV and V ($P=0.425$, Figure 1B). However, the OS among patients with tumors size ≤ 7 cm was considerably longer compared to those who had tumor size > 7 cm ($P<0.001$, Figure 1C).

Evaluation of OS by multivariate analysis

The Cox proportional hazards regression model assessment of the total cohort identified three indices as independent predictive factors for OS: ALBI grade (hazard ratio (HR): 2.10; 95% confidence interval (CI): 1.43–3.08; $P<0.001$), maximum tumor size (HR: 1.72; 95% CI: 1.16–2.56; $P=0.007$), differentiation grade (HR: 1.47; 95% CI: 1.01–2.15; $P=0.045$) (Table 2).

In the subgroup that had tumor size ≤ 7 cm, the independent predicting factors for OS included the ALBI grade (HR: 2.37; 95% CI: 1.39–4.05; $P=0.002$) and platelet count (HR: 1.80; 95% CI: 1.07–3.05; $P=0.027$). But in the subgroup with tumor size > 7 cm, ALBI grade was not identified as a major determinant of OS (Table 3).

Comparison of overall survival of patients with ALBI grades 1 and 2 HCC stratified by tumor size

For the total cohort, we observed a remarkable difference in the OS between ALBI grades 1 and 2 patients (Figure 2F). For groups I, II, and III, the ALBI grade 1 patients showed a significantly longer survival relative to the ALBI grade 2 patients ($P=0.006$, $P=0.025$, and $P=0.039$; Figures 2A, 2B, and 2C, respectively). However, the OS was comparable between patients in ALBI grades 1 and 2 in groups IV and V ($P=0.546$ and $P=0.224$; Figures 2D and 2E, respectively).

Comparison of patients' overall survival in tumor size ≤ 7 cm + ALBI grade 1 vs. tumor size ≤ 7 cm + ALBI grade 2 vs. tumor size > 7 cm subgroups

Given their importance in predicting OS, we further evaluated the effects of tumor size and ALBI grade on the HCC patient prognosis. With regards to size of tumor and ALBI grade, considerable differences in the OS were observed among the three patient subgroups (Figure 3). The tumor size ≤ 7 cm + ALBI grade 1 subgroup presented a remarkably higher OS compared to the tumor size ≤ 7 cm + ALBI grade 2 and tumor size > 7 cm subgroups. The patients in the tumor size > 7 cm subgroup exhibited the poorest OS among the three subgroups.

Discussion

Herein, the effectiveness of ALBI grading system to predict the disease progress of HCC subjects with different tumor sizes was evaluated. We observed that a large tumor size (> 7 cm) and a high ALBI grade are indicators for the poor clinical progress of patients with single HCC following surgery.

Tumor size has been regarded as one of the primary determinants of tumor recurrence and hence overall survival^{4, 14}. Huang et al. identified tumor size as a major determinant of HCC patient prognosis, particularly the patients with solitary tumors without vascular invasion¹⁵. Another study also reported that tumor size is an independent prognostic factor of recurrence-free survival among solitary HCC patients and who received curative liver resection¹⁶. However, other studies showed that large HCC does not conform to BCLC staging and treatment guidelines^{17, 18}. Among HCC patients at the BCLC stage A, single tumors > 5 cm showed similar prognosis as patients with single tumors ≤ 5 cm^{19, 20}. Herein, tumor size served as an independent predictor of overall survival for single HCC without macrovascular invasion. Patients who had a tumor size > 7 cm exhibited a significantly poorer OS compared to those who had a tumor size ≤ 7 cm. To further assess the tumor size effect on long-term survival, we compared the OS in subgroups divided by the tumor size. No differences were noted in the OS of groups I, II, and III. Groups IV and V exhibited a similar OS. These findings indicate that patients with tumor size ≤ 7 cm or tumor size > 7 cm may feature similar survival times. Therefore, patients who have a single tumor size > 7 cm ought not to be ascribed to the same BCLC stage as those with a single tumor size ≤ 7 cm.

Several factors may explain why patients who had a single tumor ≤ 7 cm showed a remarkably better OS compared to those with tumor size > 7 cm. We observed that patients whose tumors were > 7 cm presented a lower albumin level, greater blood loss, and a higher proportion of serum AFP ≥ 400 ng/ml and poor differentiation than patients with tumor size ≤ 7 cm. AFP is regarded as an important prognostic indicator for HCC undergoing liver resection^{18, 21}. A high level of preoperative AFP often indicates poor survival time after surgery²². Tumor differentiation is positively correlated with the overall survival of HCC patients after hepatectomy²³. In our study, poor differentiation was found to be an independent OS predictor in the multivariate analysis. The low histologic grade correlates with high risk of recurrence and low OS of HCC patients following curative resection²⁴.

The disease outcomes of HCC patients post-liver resection is partly affected by the existing liver physiological status. In accordance with previous studies^{10, 11, 25, 26}, we determined that ALBI grade could influence the OS of the total cohort and tumor size ≤ 7 cm subgroup. The patients who had an ALBI grade 1 presented a better survival time compared to those had an ALBI grade 2 in the total cohort. We analyzed the ALBI grade in the different subgroups to further validate its value in predicting prognoses of HCC. The OS rates were higher in ALBI grade 1 patient relative to ALBI grade 2 patients in groups I, II, and III. However, when the OS rates were analyzed in groups 4 and 5, no marked differences occurred between the subjects with ALBI grades 1 and 2. Multivariate analysis identified the lack of predictive capability of ALBI grade for the tumor size > 7 cm subgroup. Therefore, ALBI grade alone might be insufficient in determining the prognosis of HCC patients with single tumor > 7 cm. For large HCC, tumor burden could have a more significant function in determining the OS compared to the liver function. Microvascular invasion (MVI) is a critical risk factor for HCC prognosis²⁷⁻²⁹. Previous studies demonstrated that the incidence of MVI increased with tumor size³⁰. In solitary HCC, the incidence of MVI progressively increased from 4.1% to 30.7% as the tumor size increased from < 2 cm to 8.1–9.9 cm, to 12.8% in tumor size ≤ 5 cm, and to 27.7% in tumor size measuring 5.1–9.9 cm⁴. Therefore, MVI might play a more crucial function in determining the prognosis compared to liver function for large single tumors.

Theoretically, the combination of tumor size and liver function could effectively predict the prognosis of HCC following hepatic resection. We integrated tumor size and ALBI grade, to generate an accurate model for determining the prognosis of patients with a single tumor. The results showed that patients in the tumor size ≤ 7 cm + ALBI grade 1 subgroup presented a remarkably higher OS rate compared to those in the tumor size ≤ 7 cm + ALBI grade 2 and tumor size > 7 cm subgroups. Patients in the single tumor > 7 cm subgroup achieved the poorest OS among the three subgroups. Thus, the prognosis of a single small tumor might be remarkably affected by liver function, whereas tumor burden could play a leading role in the prognosis of single large tumors. In clinical practice, patients having a single tumor > 7 cm and who are undergoing liver resection may likely suffer from relapse. Thus, additional postoperative treatments may be necessary for these patients.

This study features several limitations. First, the conclusions are based on the retrospective analysis of data from a single liver center and weakened by comparably small sample size. Therefore, multicenter prospective research is required to verify and extend the results of the present study. In addition, our results refer mainly to HBV-associated HCC. Thus, further research should be conducted to validate the results among patients with non-HBV associated HCC.

In conclusion, ALBI grade is valuable in determining the prognosis of patients with single HCC with tumor size ≤ 7 cm. However, the ALBI grade shows no predictive capability among patients with a single tumor > 7 cm. Patients with a single tumor > 7 cm may constitute an independent group distinct from the classic BCLC stage A.

Declarations

Funding: This study was supported by the grants from the Research Project of Hunan Provincial Health Commission (No. B20180130) and the Big Data Project of Xiangya Medical School, Central South University.

Conflict of interest: None declared.

Author's contributions: Conceptualization: Heng Zou, Jiangjiao Zhou; Data collection: Huan Wang, Li Xiong, Yu Wen; Methodology: Heng Zou, Wenhao Chen; Writing-original draft: Wenhao Chen, Huan Wang; Writing-review and editing: Heng Zou, Jiangjiao Zhou.

References

1. Jordi Bruix, Maria Reig, Morris Sherman. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. *Gastroenterology*, 2016, 150(4):835-853
2. Vitale A, Burra P, Frigo AC, Trevisani F, Farinati F, Spolverato G, et al. Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: a multicentre study. *J Hepatol*, 2015, 62:617-624
3. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. *J Hepatol*, 2012, 56:908-943
4. Hwang S, Lee YJ, Kim KH, Ahn CS, Moon DB, Ha TY, et al. The Impact of Tumor Size on Long-Term Survival Outcomes After Resection of Solitary Hepatocellular Carcinoma: Single-Institution Experience with 2558 Patients. *J Gastrointest Surg*, 2015, 19:1281-1290
5. Zheng YW, Wang KP, Zhou JJ, Zhang ZQ, Xiong L, Wen Y, et al. Portal hypertension predicts short-term and long-term outcomes after hepatectomy in hepatocellular carcinoma patients. *Scand J Gastroenterol*, 2018, 53:1562-1568
6. Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. *J Clin Oncol*, 2015, 33:550-558
7. Kuo YH, Wang JH, Hung CH, Rau KM, Wu IP, Chen CH, et al. Albumin-Bilirubin grade predicts prognosis of HCC patients with sorafenib use. *J Gastroenterol Hepatol*, 2017, 32:1975-1981
8. Dong ZR, Zou J, Sun D, Shi GM, Ke AW, Cai JB, et al. Preoperative Albumin-Bilirubin Score for Postoperative Solitary Hepatocellular Carcinoma within the Milan Criteria and Child-Pugh A Cirrhosis. *J Cancer*, 2017, 8:3862-3867
9. Oh IS, Sinn DH, Kang TW, Lee MW, Kang W, Gwak GY, et al. Liver Function Assessment Using Albumin-Bilirubin Grade for Patients with Very Early-Stage Hepatocellular Carcinoma Treated with Radiofrequency Ablation. *Dig Dis Sci*, 2017, 62:3235-3242
10. Pinato DJ, Sharma R, Allara E, Yen C, Arizumi T, Kubota K, et al. The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma. *J Hepatol*, 2017, 66:338-346

11. Zou H, Wen Y, Yuan K, Miao XY, Xiong L, Liu KJ. Combining albumin-bilirubin score with future liver remnant predicts post-hepatectomy liver failure in HBV-associated HCC patients. *Liver Int*, 2018, 38:494-502
12. Mullen JT, Ribero D, Reddy SK, Donadon M, Zorzi D, Gautam S, et al. Hepatic insufficiency and mortality in 1,059 noncirrhotic patients undergoing major hepatectomy. *J Am Coll Surg*, 2007, 204:854-862; discussion 862-854
13. Zhou P, Chen B, Miao XY, Zhou JJ, Xiong L, Wen Y, et al. Comparison of FIB-4 Index and Child-Pugh Score in Predicting the Outcome of Hepatic Resection for Hepatocellular Carcinoma. *J Gastrointest Surg*, 2019
14. Tandon P, Garcia-Tsao G. Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. *Liver Int*, 2009, 29:502-510
15. Huang WJ, Jeng YM, Lai HS, Sheu FY, Lai PL, Yuan RH. Tumor size is a major determinant of prognosis of resected stage I hepatocellular carcinoma. *Langenbecks Arch Surg*, 2015, 400:725-734
16. Goh BK, Teo JY, Chan CY, Lee SY, Jeyaraj P, Cheow PC, et al. Importance of tumor size as a prognostic factor after partial liver resection for solitary hepatocellular carcinoma: Implications on the current AJCC staging system. *J Surg Oncol*, 2016, 113:89-93
17. Torzilli G, Belghiti J, Kokudo N, Takayama T, Capussotti L, Nuzzo G, et al. A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL/AASLD recommendations?: an observational study of the HCC East-West study group. *Ann Surg*, 2013, 257:929-937
18. Zhong JH, Pan LH, Wang YY, Cucchetti A, Yang T, You XM, et al. Optimizing stage of single large hepatocellular carcinoma: A study with subgroup analysis by tumor diameter. *Medicine (Baltimore)*, 2017, 96:e6608
19. Yang LY, Fang F, Ou DP, Wu W, Zeng ZJ, Wu F. Solitary large hepatocellular carcinoma: a specific subtype of hepatocellular carcinoma with good outcome after hepatic resection. *Annals of surgery*, 2009, 249:118-123
20. Cho YB, Lee KU, Lee HW, Cho EH, Yang SH, Cho JY, et al. Outcomes of hepatic resection for a single large hepatocellular carcinoma. *World J Surg*, 2007, 31:795-801
21. Fang KC, Kao WY, Su CW, Chen PC, Lee PC, Huang YH, et al. The Prognosis of Single Large Hepatocellular Carcinoma Was Distinct from Barcelona Clinic Liver Cancer Stage A or B: The Role of Albumin-Bilirubin Grade. *Liver Cancer*, 2018, 7:335-358
22. Chan MY, She WH, Dai WC, Tsang SHY, Chok KSH, Chan ACY, et al. Prognostic value of preoperative alpha-fetoprotein (AFP) level in patients receiving curative hepatectomy- an analysis of 1,182 patients in Hong Kong. *Transl Gastroenterol Hepatol*, 2019, 4:52
23. Shen J, Liu J, Li C, Wen T, Yan L, Yang J. The Impact of Tumor Differentiation on the Prognosis of HBV-Associated Solitary Hepatocellular Carcinoma Following Hepatectomy: A Propensity Score Matching Analysis. *Dig Dis Sci*, 2018, 63:1962-1969

24. Han DH, Choi GH, Kim KS, Choi JS, Park YN, Kim SU, et al. Prognostic significance of the worst grade in hepatocellular carcinoma with heterogeneous histologic grades of differentiation. *J Gastroenterol Hepatol*, 2013, 28:1384-1390
25. Zhang ZQ, Xiong L, Zhou JJ, Miao XY, Li QL, Wen Y, et al. Ability of the ALBI grade to predict posthepatectomy liver failure and long-term survival after liver resection for different BCLC stages of HCC. *World J Surg Oncol*, 2018, 16:208
26. Fang K-C, Kao W-Y, Su C-W, Chen P-C, Lee P-C, Huang Y-H, et al. The Prognosis of Single Large Hepatocellular Carcinoma Was Distinct from Barcelona Clinic Liver Cancer Stage A or B: The Role of Albumin-Bilirubin Grade. *Liver Cancer*, 2018, 7:335-358
27. Zhang XP, Wang K, Wei XB, Li LQ, Sun HC, Wen TF, et al. An Eastern Hepatobiliary Surgery Hospital Microvascular Invasion Scoring System in Predicting Prognosis of Patients with Hepatocellular Carcinoma and Microvascular Invasion After R0 Liver Resection: A Large-Scale, Multicenter Study. *Oncologist*, 2019,
28. Han J, Li ZL, Xing H, Wu H, Zhu P, Lau WY, et al. The impact of resection margin and microvascular invasion on long-term prognosis after curative resection of hepatocellular carcinoma: a multi-institutional study. *HPB (Oxford)*, 2019, 21:962-971
29. Shen J, Wen J, Li C, Wen T, Yan L, Li B, et al. The prognostic value of microvascular invasion in early-intermediate stage hepatocellular carcinoma: a propensity score matching analysis. *BMC Cancer*, 2018, 18:278
30. Pawlik TM, Delman KA, Vauthey JN, Nagorney DM, Ng IO, Ikai I, et al. Tumor size predicts vascular invasion and histologic grade: Implications for selection of surgical treatment for hepatocellular carcinoma. *Liver Transpl*, 2005, 11:1086-1092

Figures

Figure 1

Overall survival of patients with single tumor hepatocellular carcinoma (A) among groups I, II, and III; (B) between groups IV and V; (C) between tumor size ≤ 7 cm and tumor size > 7 cm subgroups.

Figure 2

Overall survival of patients with ALBI grades 1 and 2 in the total cohort (F), groups I (A), II (B), III (C), IV (D), and V (E). ALBI, albumin-bilirubin.

Figure 3

Overall survival curves for patients stratified by ALBI grade and tumor size following hepatic resection. Significant differences were observed in patients between tumor size $\leq 7\text{ cm}$ + ALBI grade 1 and tumor size $\leq 7\text{ cm}$ + ALBI grade 2 subgroups ($P < 0.001$); patients in tumor size $\leq 7\text{ cm}$ + ALBI grade 1 and tumor size $> 7\text{ cm}$ subgroups ($P < 0.001$); and patients in tumor size $\leq 7\text{ cm}$ + ALBI grade 2 and tumor size $> 7\text{ cm}$ subgroups ($P = 0.042$). ALBI, albumin-bilirubin.